1. Scrip
  2. >>Business

Novartis Counts On Adherence, Access And Affordability To Ensure Inclisiran’s US Success

Drug Maker Refiles PCSK9 Inhibitor Leqvio After December CRL

 
• By Alaric DeArment

The company has said coverage under medical benefit could mean $0 copays for many patients, potentially overcoming a hurdle to uptake in the biologic cholesterol market.

Doctor holding out your piggy bank wanting payment/ Your Savings To Pay Bill, insert coins to it,Stethoscope financial checkup or saving for medical insurance costs money plan fee Lifestyle concept
Novartis is aiming for adherence, access and affordability to ensure Leqvio's success in the US • Source: Shutterstock

In spite of its delayed timeline for US market entry, Novartis AG is hoping its strategy around inclisiran in atherosclerotic cardiovascular disease (ASCVD) – focusing on adherence, access and affordability – can ensure sufficient uptake of the twice-yearly PCSK9 inhibitor if it wins Food and Drug Administration approval.

The company has been busy at work developing a buy-and-bill infrastructure, as well as a network of injection centers, and...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

More from Scrip

Vertex Heralds ‘Unprecedented’ Zimislecel Type 1 Diabetes Data

 
• By Kevin Grogan

The off-the-shelf stem cell therapy shows sustained glycemic control and a high rate of insulin independence.

Pipeline Watch: Ten Approvals And Seventeen Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Obesity Treatment Could Go Global With Lilly’s Orforglipron

 
• By Andrew McConaghie

The company’s oral GLP-1 candidate has reassured on its safety at the American Diabetes Association meeting, convincing analysts it will open up new global markets.